Opus Genetics 完成 LCA5 相关遗传性视网膜疾病候选药物 Opgx-Lca5 注册性 III 期试验患者入组

美股速递
Aug 03

Opus Genetics 宣布,为其针对 LCA5 相关遗传性视网膜疾病研发的候选药物 Opgx-Lca5,已成功完成注册性 III 期临床试验的患者入组工作。这一里程碑,标志着该药物研发进程迈出了关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10